Literature DB >> 18212100

Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.

Roger G Ptak1, Philippe A Gallay, Dirk Jochmans, Andrew P Halestrap, Urs T Ruegg, Luke A Pallansch, Michael D Bobardt, Marie-Pierre de Béthune, Johan Neyts, Erik De Clercq, Jean-Maurice Dumont, Pietro Scalfaro, Kamel Besseghir, Roland M Wenger, Brigitte Rosenwirth.   

Abstract

Debio-025 is a synthetic cyclosporine with no immunosuppressive capacity but a high inhibitory potency against cyclophilin A (CypA)-associated cis-trans prolyl isomerase (PPIase) activity. A lack of immunosuppressive effects compared to that of cyclosporine was demonstrated both in vitro and in vivo. For three cyclosporines, the inhibitory potential against PPIase activity was quantitatively correlated with that against human immunodeficiency virus type 1 (HIV-1) replication. Debio-025 selectively inhibited the replication of HIV-1 in a CD4+ cell line and in peripheral blood mononuclear cells: potent activity was demonstrated against clinical isolates of various HIV-1 subtypes, including isolates with multidrug resistance to reverse transcriptase and protease inhibitors. Simian immunodeficiency virus and HIV-2 strains were generally resistant to inhibition by Debio-025; however, some notable exceptions of sensitive HIV-2 clinical isolates were detected. In two-drug combination studies, additive inhibitory effects were found between Debio-025 and 19 clinically used drugs of different classes. Clinical HIV-1 isolates that are naturally resistant to Debio-025 and that do not depend on CypA for infection were identified. Comparison of the amino acid sequences of the CypA binding domain of the capsid (CA) protein from Debio-025-sensitive and -resistant HIV-1 isolates indicated that resistance was mostly associated with an H87Q/P exchange. Mechanistically, cyclosporines competitively inhibit the binding of CypA to the HIV-1 CA protein, which is an essential interaction required for early steps in HIV-1 replication. By real-time PCR we demonstrated that early reverse transcription is reduced in the presence of Debio-025 and that late reverse transcription is almost completely blocked. Thus, Debio-025 seems to interfere with the function of CypA during the progression/completion of HIV-1 reverse transcription.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18212100      PMCID: PMC2292519          DOI: 10.1128/AAC.01324-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  93 in total

Review 1.  A three-dimensional model to analyze drug-drug interactions.

Authors:  M N Prichard; C Shipman
Journal:  Antiviral Res       Date:  1990 Oct-Nov       Impact factor: 5.970

2.  Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity.

Authors:  R W Buckheit; R Swanstrom
Journal:  AIDS Res Hum Retroviruses       Date:  1991-03       Impact factor: 2.205

Review 3.  Cyclophilin, TRIM5, and innate immunity to HIV-1.

Authors:  Elena Sokolskaja; Jeremy Luban
Journal:  Curr Opin Microbiol       Date:  2006-07-03       Impact factor: 7.934

Review 4.  Pharmacology of cyclosporine (sandimmune). I. Introduction.

Authors:  J F Borel; F Di Padova; J Mason; V Quesniaux; B Ryffel; R Wenger
Journal:  Pharmacol Rev       Date:  1990-09       Impact factor: 25.468

5.  Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients.

Authors:  Edwin DeJesus; Daniel Berger; Martin Markowitz; Calvin Cohen; Trevor Hawkins; Peter Ruane; Richard Elion; Charles Farthing; Lijie Zhong; Andrew K Cheng; Damian McColl; Brian P Kearney
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

6.  The NMR structure of cyclosporin A bound to cyclophilin in aqueous solution.

Authors:  C Weber; G Wider; B von Freyberg; R Traber; W Braun; H Widmer; K Wüthrich
Journal:  Biochemistry       Date:  1991-07-02       Impact factor: 3.162

7.  Cyclosporine-induced deterioration in patients with AIDS.

Authors:  A Phillips; M A Wainberg; R Coates; M Klein; A Rachlis; S Read; F Shepherd; H Vellend; S Walmsley; P Halloran
Journal:  CMAJ       Date:  1989-06-15       Impact factor: 8.262

Review 8.  Molecular mechanisms of immunosuppression.

Authors:  G Baumann; G Zenke; R Wenger; P Hiestand; V Quesniaux; E Andersen; M H Schreier
Journal:  J Autoimmun       Date:  1992-04       Impact factor: 7.094

9.  A continuous spectrophotometric direct assay for peptidyl prolyl cis-trans isomerases.

Authors:  C García-Echeverría; J L Kofron; P Kuzmic; D H Rich
Journal:  Biochem Biophys Res Commun       Date:  1993-02-26       Impact factor: 3.575

Review 10.  The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation--data on four cases and review of the literature.

Authors:  A Schwarz; G Offermann; F Keller; I Bennhold; J L'age-Stehr; P H Krause; M J Mihatsch
Journal:  Transplantation       Date:  1993-01       Impact factor: 4.939

View more
  55 in total

1.  Potent strategy to inhibit HIV-1 by binding both gp120 and gp41.

Authors:  Ioannis Kagiampakis; Arbi Gharibi; Marie K Mankowski; Beth A Snyder; Roger G Ptak; Kristabelle Alatas; Patricia J LiWang
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

2.  Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid.

Authors:  Sandhya Kortagere; Navid Madani; Marie K Mankowski; Arne Schön; Isaac Zentner; Gokul Swaminathan; Amy Princiotto; Kevin Anthony; Apara Oza; Luz-Jeannette Sierra; Shendra R Passic; Xiaozhao Wang; David M Jones; Eric Stavale; Fred C Krebs; Julio Martín-García; Ernesto Freire; Roger G Ptak; Joseph Sodroski; Simon Cocklin; Amos B Smith
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

3.  Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.

Authors:  Erez Pery; Ann Sheehy; N Miranda Nebane; Andrew Jay Brazier; Vikas Misra; Kottampatty S Rajendran; Sara J Buhrlage; Marie K Mankowski; Lynn Rasmussen; E Lucile White; Roger G Ptak; Dana Gabuzda
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

Review 4.  Identification of HIV inhibitors guided by free energy perturbation calculations.

Authors:  Orlando Acevedo; Zandrea Ambrose; Patrick T Flaherty; Hadega Aamer; Prashi Jain; Somisetti V Sambasivarao
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  Highly potent chimeric inhibitors targeting two steps of HIV cell entry.

Authors:  Bo Zhao; Marie K Mankowski; Beth A Snyder; Roger G Ptak; Patricia J Liwang
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

6.  Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.

Authors:  Ana M Chamoun-Emanuelli; Michael Bobardt; Bernard Moncla; Marie K Mankowski; Roger G Ptak; Philippe Gallay; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

Review 7.  HIV-1 uncoating: connection to nuclear entry and regulation by host proteins.

Authors:  Zandrea Ambrose; Christopher Aiken
Journal:  Virology       Date:  2014-02-20       Impact factor: 3.616

Review 8.  Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases.

Authors:  Carlotta Giorgi; Saverio Marchi; Ines C M Simoes; Ziyu Ren; Giampaolo Morciano; Mariasole Perrone; Paulina Patalas-Krawczyk; Sabine Borchard; Paulina Jędrak; Karolina Pierzynowska; Jędrzej Szymański; David Q Wang; Piero Portincasa; Grzegorz Węgrzyn; Hans Zischka; Pawel Dobrzyn; Massimo Bonora; Jerzy Duszynski; Alessandro Rimessi; Agnieszka Karkucinska-Wieckowska; Agnieszka Dobrzyn; Gyorgy Szabadkai; Barbara Zavan; Paulo J Oliveira; Vilma A Sardao; Paolo Pinton; Mariusz R Wieckowski
Journal:  Int Rev Cell Mol Biol       Date:  2018-06-22       Impact factor: 6.813

9.  The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1-/- myopathic mice.

Authors:  T Tiepolo; A Angelin; E Palma; P Sabatelli; L Merlini; L Nicolosi; F Finetti; P Braghetta; G Vuagniaux; J-M Dumont; C T Baldari; P Bonaldo; P Bernardi
Journal:  Br J Pharmacol       Date:  2009-06-10       Impact factor: 8.739

10.  Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics.

Authors:  Artur Kaul; Sarah Stauffer; Carola Berger; Thomas Pertel; Jennifer Schmitt; Stephanie Kallis; Margarita Zayas; Margarita Zayas Lopez; Volker Lohmann; Jeremy Luban; Ralf Bartenschlager
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.